Clinical trial NCT05085106: Safety, Tolerability and Pharmacokinetics of Felbinac Trometamol Eye Drops
Official title: A Phase I Study to the Safety, Tolerability, and Pharmacokinetic Characteristics of Felbinac Trometamol Eye Drops of Single-dose and Multiple-dose in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy
Keywords: Eye drop
Safety
Tolerability
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2021-10-20
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study is designed as single dose escalation in the healthy subjects，the subjects are divided from low dose to high dose into 5 single-dose groups of 0.025%, 0.05%, 0.1%, 0.2% and 0.3%, with both male and female subjects in each group.

The study is designed as multiple dose escalation in the healthy subjects，the subjects are divided into low dose and high dose groups of 0.1% and 0.2% with both male and female subjects in each group.

The study was designed as double-blind, all the single-dose groups containing 10 subjects except the single-dose group of 0.025% containing 8 subjects，and with 2 placebo controls in each group.
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and tolerability of felbinac trometamol eye drops of single-dose, multiple-dose, dose escalation in healthy subjects, for providing the basis for the dose setting in the later clinical study.

Detailed description: In the single-center, randomized, double-blind, placebo-controlled, single-dose dose escalation study, 48 healthy volunteers will be divided from low dose to high dose into 5 single-dose groups of 0.025%, 0.05%, 0.1%, 0.2% and 0.3%, with both male and female subjects in each group. The study was designed as double-blind, all the single-dose groups containing 10 subjects except the single-dose group of 0.025% containing 8 subjects，and with 2 placebo controls in each group.

Pharmacokinetics blood sampling in different dose groups was designed from low dose to high dose into 4 single-dose groups of 0.05%, 0.1%, 0.2% and 0.3%.

In the single-center, randomized, double-blind, placebo-controlled, multiple-dose dose escalation study, 20 healthy volunteers will be divided into low dose and high dose groups of 0.1% and 0.2%, with both male and female subjects in each group. The study was designed as double-blind, all the dose groups containing 8 subjects and 2 placebo controls.

Eligibility criteria: Inclusion Criteria:

* 18 to 45 years old, male or female;
* Weight: Male subjects should not be less than 50.0kg and female subjects should not be less than 45.0kg, BMI within the range of 19.0 and 26.0 kg/m2(Including the threshold);
* Eyes corrected visual acuity should be ≥ 1.0 in both eyes and intraocular pressure, slit lamp and fundus examination were normal or abnormality with no clinical significance;
* The female subjects should be guaranteed to take effective contraception before selected in within a month prior，and all the subjects Regardless of the gender are willing to take effective contraception and no pregnancy is planned for the next 6 months;
* Volunteer to participate in the study and sign informed consent.

Exclusion Criteria:

* With ocular diseases, including a history of inner eye surgery or laser surgery;
* Subjects who had worn contact lenses within 2 weeks prior screening or need to wear it during the study;
* Subjects who had taken any medicine including Eye ophthalmic drug within 2 weeks prior screening；
* Subjects with a history of central nervous, mental, cardiovascular, renal, liver, respiratory, metabolic and musculoskeletal systems;
* Subjects'pretest physical examination, vital signs, ELECTRO cardiogram, laboratory examination and investigator's determination of abnormality with clinical significance.
* The results of eight immunological tests(HBsAg、HBsAb、HBEAG、HABEAB、HbcAb、HCVAb、TPPA、HIV-P24 Antigen/antibody) is abnormality with clinical significance.
* A history of clinically significant allergy, especially drug allergy, allergy to aspirin or other non-steroidal anti-inflammatory drugs or known allergy to the drug component or biphenylacetic acid;
* The average daily smoking amount in the first 3 months was more than 5 cigarettes;
* Alcohol dependence is suspected or confirmed, with alcohol intake averaging more than 2 units per day for 3 months (1 unit =10 mL ethanol, i.e. 1 unit =200 mL beer at 5% alcohol or 25 mL spirits at 40% alcohol or 83 mL wines at 12% alcohol) or alcohol tests positive;
* A history of drug abuse, or positive urine tests for ketamine, morphine, methylamphetamine, dimethylene dioxymethamphetamine, or tetrahydrocannabinic acid;
* Participation in other the clinical trial within 3 months before;
* Blood donation or blood loss ≥400 mL within 3 months before;
* Pregnant or lactating women and those planning to become pregnant;
* Subjects with a history of needle and blood dizziness or intolerance to venipuncture;
* The investigator thinks it is not suitable to participate in this study.

Primary outcomes:
measure: Ophthalmic examination results in single-dose study
timeFrame: 0 hours before administration (within 60 minutes before administration), and 1 hour±10 minutes after administration
measure: Ophthalmic examination results in multiple-dose study
timeFrame: 0 hours before administration (within 60 minutes before first administration in each day), and 1 hour±10 minutes after each administration
measure: Ophthalmic examination results in single-dose study
timeFrame: screening period (from Day-14 to Day-1) , 24 hours after administration
measure: Ophthalmic examination results in multiple-dose study
timeFrame: screening period (from Day-14 to Day-1) , 48 hours after the last administration
measure: Ophthalmic examination results in single-dose study
timeFrame: screening period(from Day-14 to Day-1) , 4 hours ± 20minutes after administration
measure: Ophthalmic examination results in multiple-dose study
timeFrame: screening period(from Day-14 to Day-1) , 4 hours ± 20minutes after the last administration
measure: Intraocular pressure values in single-dose study
timeFrame: screening period(from Day-14 to Day-1) , 24 hours after administration
measure: Intraocular pressure values in multiple-dose study
timeFrame: screening period(from Day-14 to Day-1) , 48 hours after the last administration
measure: Visual acuity values in single-dose study
timeFrame: screening period(from Day-14 to Day-1) , 24 hours after administration
measure: Visual acuity values in multiple-dose study
timeFrame: screening period(from Day-14 to Day-1) , 48 hours after the last administration
measure: Adverse events (AEs) in single-dose study
timeFrame: All adverse events are collected from the signing of written informed consent up to 24 hours after drug administration.
measure: Adverse events (AEs) in multiple-dose study
timeFrame: All adverse events are collected from the signing of written informed consent up to 72 hours after the last drug administration.
measure: Serious adverse events (SAEs) in single-dose study
timeFrame: All serious adverse events are collected from the signing of written informed consent up to 24 hours after drug administration.
measure: Serious adverse events (SAEs) in multiple-dose study
timeFrame: All serious adverse events are collected from the signing of written informed consent up to 72 hours after the last drug administration.
Secondary outcomes:
measure: AUC0-t in single-dose study
timeFrame: 0 hour before administration (within 60 minutes before administration) and"10 minutes"，"20 minutes","30 minutes","45 minutes","1 hour ","1.5 hours","2 hours","3 hours","4 hours","6 hours","8 hours","12 hours"and "24 hours"after administration
measure: AUCss0-t in multiple-dose study
timeFrame: 0 hour before the last administration (within 15 minutes) and"10 minutes"，"20 minutes","30 minutes","45 minutes","1 hour ","1.5 hours","2 hours","3 hours","4 hours","6 hours","8 hours","12 hours"and "24 hours"after the last dose (steady state)
measure: Cmax in single-dose study
timeFrame: 0 hour before administration (within 60 minutes before administration) and"10 minutes"，"20 minutes","30 minutes","45 minutes","1 hour ","1.5 hours","2 hours","3 hours","4 hours","6 hours","8 hours","12 hours"and "24 hours"after administration
measure: Cmax in multiple-dose study
timeFrame: 0 hour before the last administration (within 15 minutes) and"10 minutes"，"20 minutes","30 minutes","45 minutes","1 hour ","1.5 hours","2 hours","3 hours","4 hours","6 hours","8 hours","12 hours"and "24 hours"after the last dose (steady state)
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tongren Hospital
state: Beijing
Study officials:
affiliation: Beijing Tongren Hospital
name: Xiuli Zhao, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: